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Abstract
Objectives. To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice.
Methods. We observed 232 consecutive RA patients who began tocilizumab in three rheumatology
centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated.
Results. Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 years and
average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8% of the patients had been treated
previously with anti-TNF biologics, clinical remission at Week 52 was achieved in 43.7%, radiographic
non-progression in 62.8% and functional remission in 26.4%. Retention rate at Week 52 was 71.1%, and
the same for those with or without previous anti-TNF treatment. Adverse drug reactions leading to toci-
lizumab discontinuation were observed in 15.5% of patients, the most frequent adverse drug reaction
being pneumonia in eight cases. On multivariate logistic regression analysis, DAS-28, HAQ-disability index
(HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive variables for clinical
remission at Week 52 of tocilizumab treatment. In particular, HAQ-DI was found to be a predictive variable
for remission of all three types—clinical, radiographic and functional—at Week 52 of tocilizumab
treatment.
Conclusions. In daily clinical practice, tocilizumab exhibited excellent effectiveness in established RA
patients, some of whom had failed to respond to previous anti-TNF treatment. Although further detailed
safety findings are required, this study provides valuable real-world findings on the management of RA
with tocilizumab.
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Introduction
Pro-inflammatory cytokines play a fundamental role in the
inflammatory processes leading to destructive arthritis in
patients with RA [1, 2]. Biological agents against pro-
inflammatory cytokines such as TNF-a have dramatically
changed the management of patients with RA [1, 2]. It is
now recommended to treat RA patients to achieve clinical
remission by early and tight control of disease activity with
intensive medication [3, 4]. Recent clinical trials have
shown that treatment with anti-TNF biologics in combin-
ation with MTX in early RA can lead to clinical remission
in 50% of patients [5]; however, the remaining half of
the patients are either those not able to achieve clinical
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Eremission or discontinued anti-TNF biologics and switched
to other medications [68]. A new biological agent, tocili-
zumab, targeting the IL-6 receptor has recently been
approved for use in patients with RA in more than
40 countries around the world, including Japan, drawing
attention to the effectiveness and safety of tocilizumab in
clinical practice [911]. Generally, randomized clinical
trials (RCTs) are considered the gold standard for evalu-
ation of the efficacy of newly developed agents. However,
RCTs are artificial and may not reflect efficacy and safety
in the real rheumatology world.
While we have reported the effectiveness of tocilizumab
at Week 24 [12], there is no report that evaluates all effi-
cacy with regard to clinical remission, structural remission
and functional remission of tocilizumab comprehensively
under daily clinical practice. Hence we undertook the
Retrospective Actemra Investigation for Optimal Needs
of RA Patients (REACTION 52-week study) to confirm the
efficacy and safety of tocilizumab in daily clinical practice.
Patients and methods
Patients
All RA patients included in this study fulfilled the ACR
classification criteria [13]. After the approval of tocilizumab
in April 2008 in Japan, all patients from three rheuma-
tology centres in Japan (the Division of Rheumatology
and Clinical Immunology, Department of Internal Medicine,
Saitama Medical Center, Saitama Medical University,
Saitama; the First Department of Internal Medicine, School
of Medicine, University of Occupational & Environmental
Health Japan, Kitakyushu; and the Institute of
Rheumatology, Tokyo Women’s Medical University) who
had started to receive tocilizumab by March 2009 were
consecutively registered into this study and were followed
up every 4 weeks at the time of infusion. We analysed a
total of 232 RA patients who had been observed for
52 weeks from the initial infusion of tocilizumab.
The REACTION study was a retrospective observational
study using anonymized information, and conformed to
standard tocilizumab treatment proposed by the Japan
College of Rheumatology (JCR). Patients’ written consent
was obtained according to the Declaration of Helsinki.
Tocilizumab treatment and assessment of
effectiveness
Tocilizumab was infused every 4 weeks at a dose of 8mg/kg
according to the drug labelling and the tocilizumab ther-
apy guidelines of the JCR [14]. In the JCR guidelines, toci-
lizumab is recommended for patients who show
an inadequate response despite treatment for at least
3 months with the maximum permissible dose of one of
the non-biologic DMARDs. Demographic data, including
disease duration and concomitant therapy, were collected
from the medical charts. The following parameters were
evaluated every 4 weeks for 52 weeks following the initial
infusion of tocilizumab: tender joint count (TJC) 28, swol-
len joint count (SJC) 28, patient’s global assessment
(Pt-GA) of disease activity, physician’s global assessment
(Ph-GA) of disease activity, ESR, CRP, MMP-3 and
HAQ-disability index (HAQ-DI). Disease activity was as-
sessed by the DAS-28 that was calculated according to
the authorized formula [15]. Although there were no cri-
teria for measuring CRP, ESR and MMP-3 in this study
protocol, these items are approved for monthly monitoring
in RA by the Japanese health insurance system.
Eventually, ESR, CRP and MMP-3 were performed at
each visit in three institutions as routine clinical practice
for all patients treated with tocilizumab.
Among the 232 patients in this study, X-ray images of
both the hands and feet at 0 and 52 weeks or last obser-
vation were available for 149 patients for assessing radio-
graphic damage. The images were read by two
independent, well-trained rheumatologists according to
the previously reported van der Heijde-modified Sharp
(vdHSharp) method [16, 17]. Estimated yearly progres-
sion was calculated as previously reported [17, 18]. The
last observation carried forward (LOCF) method was used
in each analysis and radiographic data were extrapolated
to 52 weeks. Clinical remission was defined as a DAS-28
of <2.6, structural remission was defined as a change in
total vdHSharp score of 40.5 from baseline to Week 52,
and functional remission was defined as HAQ-DI of 40.5,
as previously reported [17].
Statistical analysis
The LOCF method was used in each analysis. Baseline
variables of RA patients were analysed for association
with clinical, structural and functional remissions at
Week 52 using Pearson’s chi-square test (for categorical
variables) and Student’s t-test (for continuous variables).
Univariate logistic analysis was used to screen for poten-
tial predictive variables, and a stepwise selection process
was used to generate a multivariate regression model for
predicting remission at Week 52 of tocilizumab treatment.
All statistical analyses were performed with JMP version
8.0.2 statistical software (SAS Institute Inc., Cary, NC,
USA).
Results
Demographic data of patients from three institutions
Baseline characteristics of the 232 patients enrolled in this
study are shown in Table 1. Mean age was 59.1 years and
mean duration of the disease was 12.4 years, indicating
that the RA patients in this study were established and
advanced. Disease activity was high, as shown by the
mean DAS-28 of 5.6 and mean CRP level of 3.1mg/dl.
Notably, MTX and glucocorticoids (GCs) were concomi-
tantly used in 56 and 66% of the patients, respectively,
and 62.8% of the patients had previously experienced
treatment with anti-TNF biologics.
Changes in DAS-28 and HAQ-DI during 52 weeks of
tocilizumab treatment
As shown in Fig. 1, the DAS-28 score significantly
decreased from 5.6 (1.3) at baseline to 4.4 (1.5) at Week
4, 3.8 (1.7) at Week 12, 3.3 (1.6) at Week 24 and 3.2 (1.7)
www.rheumatology.oxfordjournals.org 1909
Tocilizumab in RA in clinical practiceat Week 52 (P<0.0001). Disease activity status changed
significantly from high disease activity at baseline to clin-
ical remission or low disease activity during treatment with
tocilizumab (P<0.0001). Clinical remission was obtained
in 14.8% of the patients at Week 4, 27.7% at Week 12,
39.2% at Week 24 and 43.7% at Week 52, indicating that
clinical remission was achieved for 44% of patients and
that the rate nearly plateaued at Week 24 in this patient
population. Notably, only 14% of the patients showed no
response at Weeks 24 and 52. In addition, clinical remis-
sion, even when assessed by non-responder imputation
methods, was 12.1, 23.3, 34.1 and 39.7% at Weeks 4, 12,
24 and 52, respectively, showing 34% lower than that
obtained by the LOCF method. Significant improvements
in clinical parameters were observed and the percentage
reduction for each parameter at Week 52 compared with
at baseline was 63.8% for SJC, 60.5% for TJC, 33.7% for
Pt-GA, 70.4% for ESR, 82.6% for CRP and 56.0% for
MMP-3.
HAQ-DI similarly decreased significantly from 1.56 (0.80)
at baseline to 1.29 (0.87) at Week 52 (P=0.0009).
However, improvement in HAQ-DI compared with base-
line score (change in HAQ-DI50.22) was observed in
only 45.6% of patients at Week 52. Although functional
remission (HAQ-DI40.5) increased significantly from
12.4% at baseline to 26.4% at Week 52, categorical ana-
lysis of HAQ-DI did not show any statistical change
(P=0.1352).
Effects of medication on clinical and functional
response
As shown in Fig. 2, DAS-28 at Week 52 was signifi-
cantly lower in patients receiving concomitant MTX than
in those not receiving it [2.92 (1.46) and 3.45 (1.82), re-
spectively; P=0.0336]. HAQ-DI was also significantly
lower in those receiving MTX than in those not receiving
it [1.12 (0.83) vs 1.55 (0.85); P=0.0005]. In contrast,
DAS-28 at Week 52 was significantly higher in patients
receiving concomitant GCs than in those not receiving
them [3.34 (1.58) vs 2.87 (1.79); P=0.0037]. Again, HAQ-
DI at Week 52 was also higher in patients receiving GCs
than in those not receiving them [1.40 (0.88) vs 1.07 (0.82);
P=0.0071). However, there was no significant difference
in either DAS-28 or HAQ-DI at Week 52 between patients
who had or had not received previous treatment with
anti-TNF biologics.
Inhibition of radiographic damage by tocilizumab
treatment
Radiographic damage was evaluated in 149 of the 232 pa-
tients. Most baseline parameters as well as clinical and
functional response at Week 52 did not differ significantly
between the patients who underwent radiographic evalu-
ation (n=149) and those who did not (n=83) (data not
shown).
There was no significant difference between total
vdHSharp score at Week 0 and that after 52 weeks of
tocilizumab treatment [140.5 (101.2) vs 142.1 (101.3);
P = 0.8916], and erosion score and joint space narrowing
(JSN) score were similarly not significantly changed. The
mean change from Week 0 to 52 of tocilizumab treatment
was 1.07 (2.87) for total vdHSharp score, 0.50 (1.34) for
erosion score and 0.58 (1.95) for JSN score, which ap-
pears to be clinically sufficient for tocilizumab to inhibit
structural damage. As judged by a change in total
vdHSharp score of 40.5, 62.8% of the patients
showed no radiographic progression (Fig. 3a). For the
structural damage, treatment with tocilizumab greatly
reduced the estimated yearly progression of the total
vdHSharp score from 20.8 (22.9) at baseline to 1.1 (2.9)
(Fig. 3b). There were no differences in the effect of struc-
tural damage among patients with different durations of
disease. Interestingly, progression of joint destruction was
similar with or without concomitant MTX, GCs or previous
use of anti-TNF biologics. Each estimated yearly progres-
sion by RA patients treated with or without anti-TNF bio-
logics was dramatically decreased from 18.3 (19.3) at
baseline to 0.9 (2.4) at 52 weeks (96% reduction) and
24.8 (27.4) at baseline to 1.4 (3.5) at 52 weeks (94% re-
duction), respectively.
Retention rate during 52 weeks of treatment with
tocilizumab
The retention rate of this study was 92.0% at Week 12,
83.0% at Week 24 and 71.1% at Week 52. Sixty-seven
(28.9%) patients discontinued tocilizumab treatment be-
cause of adverse events (AEs) (38/67, 56.7%), lack of ef-
ficacy (21/67, 31.3%), remission (1/67, 1.5%) and other
reasons (7/67, 10.4%). Retention rate was higher for pa-
tients with concomitant MTX than for those without it (77.1
vs 66.0%), and was lower for those with concomitant GCs
than those without (68.7 vs 78.4%), while it did not differ
between those with or without previous treatment with
anti-TNF biologics (72.5 vs 70.9%).
TABLE 1 Demographic and clinical features of the RA
patients (n = 232)
Clinical parameters Mean (S.D.)
Median
(interquartile range)
Age 59.1 (13.3) 61.0 (53.068.0)
Gender, female, % 84.3
Duration, years 12.4 (11.1) 10.0 (4.018.0)
Steinbrocker’s
stages I/II/III/IV, %
7.2/30.5/17.0/45.3
Steinbrocker’s
class 1/2/3/4, %
5.0/72.2/22.4/0
DAS-28 5.6 (1.3) 5.6 (4.96.6)
SJC (028) 7.7 (5.6) 7 (311)
TJC (028) 7.9 (6.4) 6 (312)
ESR, mm/h 63 (29) 64 (4485)
CRP, mg/dl 3.1 (2.9) 2.5 (0.94.6)
Pt-GA (VAS/100mm) 56 (24) 54 (4076)
Concomitant MTX, % 55.6
Dose of MTX,
mg/week
8.6 (3.1) 8.0 (6.010.0)
Concomitant GCs, % 66.4
Dose of GCs,
mg/day
5.2 (3.1) 5.0 (3.06.0)
Previous
anti-TNFs, %
62.8
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functional remission at Week 52
Since there are substantial confounding factors contribut-
ing to the clinical, radiological and functional responses to
tocilizumab treatment, we next searched for independent
predictive baseline parameters for clinical, structural and
functional remission at Week 52. Based on the results of a
univariate logistic regression analysis, age, disease dur-
ation, DAS-28, HAQ-DI, dose of MTX and dose of GCs
at baseline were selected as significant variables for clin-
ical remission at Week 52; estimated yearly progression
of total vdHSharp score, HAQ-DI and dose of GCs at
baseline were selected as significant variables for struc-
tural remission at Week 52; and age, disease duration,
DAS-28, total vdHSharp score, HAQ-DI and dose of
MTX at baseline were selected as significant variables
for functional remission at Week 52 (Table 2). Multiple re-
gression analysis showed that DAS-28, HAQ-DI, dose
of MTX and dose of GCs at baseline were identified as
independent predictive variables for clinical remission at
Week 52. Yearly progression of total vdHSharp score
and dose of GCs were found to be the independent pre-
dictive variables for structural remission at Week 52:
in addition, although HAQ-DI was not a statistically sig-
nificant predictive variable, it gave an adjusted odds ratio
of 0.624 (Table 3). Finally, baseline HAQ-DI was identi-
fied as an independent predictive variable for functional
remission at Week 52, with an adjusted odds ratio of
0.582.
Safety
In total, 133 AEs and 26 serious AEs (SAEs) were
observed in 58 (25.0%) and 26 (11.2%) of 232 patients,
respectively. Most of the AEs were infections and labora-
tory tests. In the category of SAEs, serious infections were
reported in 10 (4.3%) patients, and the most common
serious infection was pneumonia (4 points, 1.7%). Skin
infection and oesophageal candidiasis were also reported
in one patient each as SAEs necessitating discontinuation
of tocilizumab treatment. In addition, there were two
cases each of cerebral bleeding, malignancy (breast and
cervix), liver dysfunction, skin eruption and exacerbation
FIG.1Change in DAS-28 and HAQ-DI scores over 52 weeks of tocilizumab treatment. Upper panels show the change in
DAS-28 [left: distribution of the values, mean (S.D.), and median with first and third quartile points of DAS-28; right:
categorical distribution of disease activity status]. Lower panels show the change in HAQ-DI [left: distribution of the
values, mean (S.D.), and median with first and third quartile points of HAQ-DI; right: categorical distribution of disability
status]. HDA: high disease activity; MDA: moderate disease activity; LDA: low disease activity.
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failure, myocardial infarction, chest pain, necrotizing pan-
creatitis and skin ulcer. Gastrointestinal bleeding, gastro-
intestinal perforation and anaphylaxis were also observed
in one patient, leading to discontinuation of further tocili-
zumab treatment. The most common laboratory abnorm-
alities were increases in lipids, including total, low- and
high-density lipoprotein cholesterol in 5 (2.2%) of 232 pa-
tients and liver function abnormality, including aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) elevation in 7 (3.0%) patients. The elevation of
serum bilirubin and cytopenia (white blood cells and plate-
lets decreasing) were also reported in two patients each,
leading to discontinuation of tocilizumab treatment.
Discussion
In this study, 44% of patients with established RA and
high disease activity achieved clinical remission at Week 52
of tocilizumab treatment, and radiographic non-progression
was observed in >60% of patients. Although it is difficult
to compare these results with those of other biologics
because the patient background factors in each study dif-
fered, the efficacy of tocilizumab might be equivalent to or
superior to anti-TNF agents compared with a similar type
of study, whose DAS-28-CRP remission rate at Week 52
was 27.6% [19].
The Chugai Humanized Anti-Human Recombinant
Interleukin-6 Monoclonal Antibody (CHARISMA) study
[20] suggests that tocilizumab in combination with MTX
may be superior to tocilizumab monotherapy, suggesting
in turn that the rate of clinical remission with tocilizumab
plus MTX combination therapy may also be higher as well.
The present study clearly showed that clinical and func-
tional remission rates at 52 weeks were significantly
higher for RA patients receiving MTX than those without
MTX, whereas in marked contrast, remission rates were
significantly lower for those receiving GCs than for those
not receiving them. These findings were further supported
by the observation that the retention rate of tocilizumab
FIG.2DAS-28 and HAQ-DI at Week 52 of tocilizumab
treatment in RA patients with or without (a) concomitant
MTX; (b) GCs; (c) previous treatment with anti-TNF
biologics. Distribution of the values, mean (S.D.) and
median with first and third quartile points of each
clinical parameter are shown.
FIG.3Effects of radiographic damage before and
52 weeks after tocilizumab treatment by (a) the cumulative
probability in total vdHSharp score and (b) estimated
yearly progression of total vdHSharp score.
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without it, and lower for patients with GCs than for those
without them. The question might be raised whether con-
comitant use of MTX and GCs is affected by a number of
confounding factors. However, multivariate logistic re-
gression analysis demonstrated that higher doses of
MTX and lower doses of GCs, in addition to baseline
DAS-28 and HAQ-DI, each independently contributed to
achievement by tocilizumab of clinical remission at 52
weeks. The retention rates were not significantly different,
and instead were consistent with our findings for DAS-28
and HAQ-DI at Week 52 in patients with and without these
medications, suggesting that patients who do not achieve
a satisfactory response or who have safety issues should
discontinue tocilizumab.
The Study of Active Controlled Monotherapy Used for
Rheumatoid Arthritis, An IL-6 Inhibitor (SAMURAI) study
demonstrated that, compared with DMARDs, tocilizumab
monotherapy significantly inhibited progression of struc-
tural damage in Japanese RA patients [21]. In addition,
preliminary results reported from the Tocilizumab Safety
and the Prevention of Structural Joint Damage (LITHE)
study showed that, compared with MTX alone, tocilizu-
mab plus MTX treatment resulted in significantly less pro-
gression of joint destruction [22]. In the present study,
X-ray images at baseline and at Week 52 of tocilizumab
treatment were available for 149 of 232 patients, allowing
us to evaluate the radiographic effect of tocilizumab. The
radiographic data obtained in this study are consistent
with the results of previous clinical trials, and the multi-
variate logistic regression analysis suggested the new hy-
pothesis that concomitant GCs compromise the inhibition
of structural progression by tocilizumab. As stated above,
the duration of disease in patients enrolled in this study
TABLE 2 Logistic regression analysis for the possible association between baseline parameters and clinical, structural
and functional remissions at 52 weeks by tocilizumab treatment
Baseline clinical parameters
Clinical remission Structural remission Functional remission
Chi-square P-value Chi-square P-value Chi-square P-value
Age 13.39 0.0003 0.28 0.5966 24.89 <0.0001
Gender 2.81 0.0938 0.04 0.8507 0.17 0.6819
Disease duration 4.68 0.0305 0.63 0.4761 10.11 0.0015
DAS-28 15.74 <0.0001 1.86 0.1726 21.55 <0.0001
MMP-3 1.41 0.2354 1.59 0.2066 2.40 0.1211
Total vdHSharp score 0.73 0.3927 0.28 0.5966 4.75 0.0293*
Estimated yearly progression
of total vdHSharp score
0.90 0.3416 13.18 0.0003 0.43 0.5131
HAQ-DI 24.52 <0.0001 4.21 0.0403 96.42 <0.0001
Comorbidity 0.06 0.8075 0.71 0.3987 0.79 0.3740
Dose of MTX 20.55 <0.0001 0.05 0.8187 6.92 0.0085
Dose of GCs 5.12 0.0237 5.75 0.0165 1.97 0.1609
Previous anti-TNFs 0.32 0.5736 0.44 0.5087 0.12 0.7279
TABLE 3 Multiple logistic regression models for the baseline parameters predictive of clinical, structural and functional
remissions at 52 weeks of tocilizumab treatment
Baseline
clinical
parameters
Clinical
remission
Structural
remission
Functional
remission
Adjusted odds ratio
(95% confidence
interval) P-value
Adjusted odds ratio
(95% confidence
interval) P-value
Adjusted odds ratio
(95% confidence
interval) P-value
Duration, years   1.022 (0.9871.061) 0.2295
DAS-28 0.673 (0.5000.890) 0.0069   
Estimated yearly
progression
of total vdHSharp
score
 0.967 (0.9450.986) 0.0021 
HAQ-DI 0.569 (0.3590.886) 0.0141 0.624 (0.3811.002) 0.0553 0.582 (0.3600.919) 0.020
Dose of MTX,
mg/week
1.134 (1.0621.214) 0.0002   
Dose of GCs,
mg/day
0.898 (0.8090.991) 0.0368 0.879 (0.7860.978) 0.0202 
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significantly high, with 20.8 (1.3) at baseline. Considering
the results of the impact on radiographic and clinical
response to infliximab therapy concomitant with metho-
trexate in patients with rheumatoid arthritis by trough
serum level in a dose escalating (RISING) study, in
which we reported a disease duration of 8 years and
mean estimated yearly progression of 8.1 (9.1) [23], the
present study included patients with remarkably severe
clinical features with long disease duration and progres-
sive joint destruction. Irrespective of these severe condi-
tions, the 95% inhibitory effect of tocilizumab indicates
how powerful its inhibition of joint destruction is.
Surprisingly, we found that tocilizumab inhibits the radio-
graphic damage, not only in patients treated without TNF
inhibitors, but also in those treated with TNF inhibitors.
Although further research is needed, our findings suggest
that the pathological condition of RA is dependent on
TNF. The good results obtained with tocilizumab are con-
sistent with those of both domestic and foreign studies.
On the other hand, functional remission was achieved in
26.4% of the patients at 52 weeks, which is lower than the
clinical remission rate at 52 weeks (43.7%) and that of
radiographic non-progression at 52 weeks (62.8%). The
longer duration of disease and high HAQ-DI at baseline
may be responsible for the lower functional remission rate
observed in the present study. Although Nagasawa et al.
[17] reported that the incidence of HAQ remission
(HAQ40.5) after 2 years of treatment with infliximab
was 41.6%, it is difficult to compare this result with our
own because the methods of statistical analysis used in
these two studies differed markedly. Smolen et al. [24]
analysed the damage-associated HAQ-DI score in the
Best Life in RA (BELIRA) trial and seven pivotal clinical
trials including anti-TNF biologics, MTX and LEF [24].
According to their report, damage-associated HAQ-DI
corresponds to 0.01 per point of total vdHSharp score.
The total vdHSharp score of 140.5 at baseline in this
study appears to correspond to a damage-associated
HAQ-DI of 1.41, and thus maximum improvement after
tocilizumab treatment may be assumed to be an
HAQ-DI of 1.56 at baseline minus 1.41, which is 0.15.
The real change observed in this study (0.27) was better
than that determined based on the above assumption.
Considering factors such as the severe baseline HAQ in
the present study, our findings suggest that administration
of tocilizumab before worsening of HAQ, in the very early
stage, might lead to attaining rates of high clinical, struc-
tural and functional remission. We should master use of
tocilizumab towards achievement of a higher treatment
goal in RA patients.
Although the duration of disease in the patients in this
study was long and 60% of the patients had used anti-
TNF agents previously, the incidences of SAEs and ser-
ious infections were comparable with those in the RISING
study, in which the incidences of SAEs and serious infec-
tions were 11.6 and 5.2%, respectively [23]. These results
indicate that attention must be paid to the onset of serious
infections, including pneumonia, during tocilizumab
treatment as well as with anti-TNF agents. Most of the
laboratory test abnormalities in this study were transient
and not associated with SAEs. These findings indicate
that the safety profile of tocilizumab was acceptable in
actual clinical practice.
In conclusion, the REACTION study showed that clinical
remission could be achieved in 40% of patients and
radiographic non-progression could be achieved in
60%. Tocilizumab was well tolerated over 52 weeks,
and the most frequent adverse drug reaction was pneu-
monia. Although functional remission was obtained in
28% of the patients at Week 52, it was confirmed that
higher remission rates may be attained with earlier admin-
istration of tocilizumab before worsening of HAQ.
Additionally, the multivariate logistic regression model
that we used provided insights into how the use of tocili-
zumab can be improved in clinical practice.
Rheumatology key messages
. The REACTION study showed the clinical, structural
and functional response to tocilizumab in RA pa-
tients in real-world clinical practice.
. A multivariate logistic model provided insights into
how the use of tocilizumab can be further
improved.
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